中文

飞凯材料 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-22
ItemAmountY/Y
Revenue¥0.87B+24.6%
Gross profit¥0.35B
Operating income¥0.16B
Net income¥0.14B+12.5%
Gross margin39.6%Net margin 16.0%
Revenue Q/Q-1.2%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.53B60.4%
R&D¥0.05B5.2%
SG&A¥0.12B13.3%
Tax & other¥0.02B2.2%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

天利科技劲拓股份花园生物宝色股份汉宇集团博济医药科隆股份九强生物凯发电气道氏技术正业科技金盾股份

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies